VERA THERAPEUTICS INC CLASS A (VERA)
Health Care · Biotechnology · NASDAQ
Vera Therapeutics is a commercial-stage biotech pioneer targeting B-cell-driven autoimmune diseases, currently focused on its lead BAFF/APRIL inhibitor for IgA nephropathy.
What VERA THERAPEUTICS INC CLASS A does
Vera Therapeutics is a commercial-stage biotechnology company focused on developing and commercializing therapies for autoimmune diseases, with an initial emphasis on kidney disorders. Its lead commercial product is TRUTAKNA (atacicept-vymj), a B-cell activating factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) inhibitor used to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). The company is also evaluating the therapeutic potential of atacicept across various other autoimmune and kidney-related conditions.
Themes: Autoimmune diseases, Kidney / Renal medicine, B-cell therapy, IgA Nephropathy (IgAN), Rare disease therapeutics
Fundamentals
- Price$32.28 as of 2026-08-21 close
- Market cap$2.3B as of 2026-08-21
- 1-year return+42.7% 2025-08-21 close $22.61 → 2026-08-21 close $32.28
- P/En/a earnings data not available
- ROE-74.9% as of 2026-08-24
- Debt / equity0.15 as of 2026-08-24
- Beta0.99 as of 2026-08-24
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How VERA compares in its sector
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
VERA is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
38.7 #1448 of 1,704 scored · #215 of 240 in Health Care
Setup 56th: over the past year its closes ranged, and it has retraced well over two thirds of its move over the past year — 68% of it; volume and participation 55th: it gapped 8.3% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; weakest is trend 23rd: a strong downtrend, with sellers in control.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How VERA THERAPEUTICS INC CLASS A looks technically
VERA THERAPEUTICS INC CLASS A (VERA) is trading 17.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 44 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive). It made a new 20-day low about 7 trading days ago. It is 42.4% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 17.0% below its 200-day average, the long-term trend line — a long-term downtrend | -17.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $36.15 | $36.15 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $38.89 | $38.89 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 44 trading days ago — a "death cross", a bearish long-term signal | 44 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with sellers in control | 28.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30) | 46.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($28.86 to $33.48) — its "stochastic" reading is 74 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 73.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $56.05 | $56.05 |
|---|---|---|
| From the 52-week high | it is 42.4% below its 52-week high (its highest price of the past year) | -42.4% |
| Above the 52-week low | it is 53.4% above its 52-week low (its lowest price of the past year) | +53.4% |
| Below the 52-week high | it is 42.4% below its highest point of the past year | 42.4% |
| Since a 20-day breakout | it made a new 20-day low about 7 trading days ago | 7 sessions |
| Since a 55-day breakout | it made a new 55-day low about 7 trading days ago | 7 sessions |
| All-time high | its highest closing price on record is $56.05 (set on 2025-12-24) | $56.05 |
| Given back of the 52-week move | over the past year its closes ranged ($21.27 to $55.67), and it has given back well over two thirds of its rise from last year’s low — 68% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $33.31 to $34.41. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 68.0% |
| From the all-time high | it is 42.4% below its all-time high | -42.4% |
| Nearest price level | it is trading 1.2% above a support level at $31.90 — a price it turned at four times since 2025-01-13, most recently on 2025-11-12. Since 2024-08-21 it has 6 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.2% |
| All-time low | its lowest closing price on record is $5.20 (set on 2023-01-06) | $5.20 |
| Above the all-time low | it is 520.7% above its all-time low | +520.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 32nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.87 between its high and its low — about 5.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.87 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $29.03 and $34.54 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $29.03 – $31.78 – $34.54 |
| Typical daily range (% of price) | its price moves about 5.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.8% |
| Stretch from the 200-day average | it is trading 3.5 daily ranges below its 200-day average price (17.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.63× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 5.7% since the prior reading | -5.7% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.5% |
|---|---|---|
| Open gap | it gapped 8.3% above the previous close 5 sessions ago and has not traded back through the level it left behind at 28.89 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +8.3% |
| Gap filled | a 2.5% gap up opened on 2026-08-07 has been "filled" 9 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 9 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 15.5 percentage points (the stock lost 13.2% while the market gained 2.3%) | -15.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 9.1 percentage points (the stock lost 6.0% while the market gained 3.1%) | -9.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 33.8 percentage points (the stock lost 22.7% while the market gained 11.1%) | -33.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 22.3 percentage points (the stock gained 42.7% while the market gained 20.5%) | +22.3% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 14% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 6.6% of the share price. | -14.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 17% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $38.92 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -17.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $31.28 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | +3.2% |
Price levels it has turned at before
VERA last closed at $32.27 on 2026-08-21. Since 2024-08-21 it has turned at 6 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $31.90 | Support | 1.2% below the last close | turned there four times · 2025-01-13 to 2025-11-12 |
| $32.97 | Resistance | 2.1% above the last close | turned there three times · 2025-06-03 to 2026-08-07 |
| $30.57 | Support | 5.3% below the last close | turned there twice · 2025-03-03 to 2026-06-03 |
| $36.63 | Resistance | 13.5% above the last close | turned there twice · 2026-05-28 to 2026-07-02 |
| $37.71 | Resistance | 16.8% above the last close | turned there four times · 2024-10-09 to 2026-03-30 |
| $25.97 | Support | 19.5% below the last close | turned there three times · 2025-02-14 to 2025-05-05 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · Analyst price target recently CUT · lagging the market · Near the golden pocket (has given back about two thirds of its 52-week move) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.21 mean, 1=Strong Buy…5=Strong Sell) — 14 analysts
- Mean price target$77.14 range $34.00 – $100.00; median $79.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for VERA
- Consensus EPS estimate-$1.59 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on third-party manufacturers for product supply","Limited history of commercial operations and revenue generation","Dependency on the clinical success and regulatory approval of product candidates beyond the lead indication"]
What changed in the latest 10-Q
AI-assisted comparison of VERA's 10-Q filed 2026-05-07 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to Annual Report on Form 10-K for year ended December 31, 2025, filed February 26, 2026 (newer filing) vs. December 31, 2024, filed February 28, 2025 (older filing)
- Added specific ORIGIN 3 efficacy results: 46% reduction from baseline in UPCR and 42% reduction compared to placebo (p<0.0001)
- Added statement that incidence of adverse events was generally balanced between atacicept and placebo groups, with fewer serious adverse events with atacicept than placebo, no safety signals of immunosuppression, and no deaths in either group
- Added that in November 2025, company submitted a Biologics License Application (BLA) for atacicept to FDA through Accelerated Approval Program
- Added that on January 7, 2026, FDA granted priority review and assigned PDUFA target action date of July 7, 2026
- Added that if approved, atacicept would be first B-cell modulator inhibiting both BAFF and APRIL for IgAN, offering autoinjector for at-home self-administration
- Added explicit statement that ORIGIN 3 met the primary efficacy endpoint of reduction in proteinuria as measured by 24-hour UPCR at week 36
- Added reference to anti-phospholipase A2 receptor (PLA2R) or anti-nephrin autoantibodies in PIONEER trial description
- Added statement that initial results from Phase 2 PIONEER trial are expected in second quarter of 2026
- Added specific mention of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and lupus nephritis (LN) as potential future indications
- Removed:
- Removed description of company as 'late clinical-stage biotechnology company' (older filing stated this; newer filing just states 'biotechnology company')
- Removed reference to 'fully humanized' descriptor for TACI-Fc fusion protein (older filing); newer filing states 'native human'
- Removed 'In April 2025, we completed full enrollment of ORIGIN 3' statement
- Removed 'In the second quarter of 2025, we announced positive primary endpoint results from ORIGIN 3'
- Removed statement about evaluating monthly dosing of atacicept in participants with IgAN
- Removed reference to 'anti-PLA2R antibodies or other auto-antibodies' (newer filing specifies 'PLA2R or anti-nephrin autoantibodies')
- Removed reference to 'autoimmune hemolytic anemia' from list of potential future indications
- Removed statement 'We hold global developmental and commercial rights to all of our pipeline molecules'
- Removed sentence 'Since our inception, we have devoted substantially all of our resources to our research and development efforts, pre-clinical studies and clinical trials, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations'
- Removed financial data section referencing cash position as of September 30, 2025 ($497.4 million) and December 31, 2024 ($640.9 million), and net losses for three-month periods
- Reworded:
- Changed 'pipeline in a molecule' to 'pipeline-in-a-molecule' (hyphenation change)
- Changed description of phase from 'Phase 2 PIONEER clinical trial' to 'Phase 2 PIONEER clinical trial' but added specification of which kidney diseases in parenthetical reference
- Changed 'atacicept's safety profile was comparable to placebo' (older) to 'Atacicept's safety profile appeared favorable, and comparable to placebo' (newer)
- Changed 'ORIGIN EXTEND, a long-term Phase 2 extension study that offers open-label atacicept to participants' (older) to 'ORIGIN EXTEND, a long-term Phase 2 extension study that offers atacicept to participants' (newer, removing 'open-label')
- Changed 'until commercial availability in their country or region' (older) to 'until, if approved, commercial availability in their country or region' (newer, adding conditional 'if approved')
- Notes:
- The text appears to be truncated at the end of both versions, so the complete section comparison may not capture all changes in the full MD&A
- Financial data and related discussion in the older filing have been removed or appear in different location in the newer filing version provided
Risk Factors
- Added:
- In newer filing (2026-05-07): Cash position increased to $596.8 million as of March 31, 2026 (compared to $497.4 million as of September 30, 2025 in older filing)
- Removed:
- In older filing (2025-11-05): References to 'Class A common stock' in opening sentence removed in newer filing, now states 'common stock'
- In older filing (2025-11-05): Description 'late-stage biotechnology companies' changed to 'biotechnology companies' in newer filing
- In older filing (2025-11-05): Reference to 'immunological and inflammatory diseases' changed to 'immunological and rare diseases' in newer filing
- In older filing (2025-11-05): Specific product pipeline references removed - older filing lists 'continue our ongoing and planned research and development of atacicept...initiate or continue nonclinical studies and clinical trials for atacicept, MAU868, VT-109...continue our research and development of MAU868...advance our research and development of VT-109' - newer filing generalizes to 'initiate or continue nonclinical studies and clinical trials for our product candidates'
- In older filing (2025-11-05): Specific reference to 'Advancing the development of atacicept, MAU868, VT-109, and any future product candidates' changed to generic 'Advancing the development of our product candidates' in newer filing
- In older filing (2025-11-05): Specific disease indication references (IgAN, BK viremia in kidney transplant recipients, autoimmune-related conditions) removed in newer filing
- Reworded:
- Newer filing (2026-05-07) changes 'would be if we had' to 'would it be if we had' in context of predicting success with longer operating history
- Newer filing (2026-05-07) removes comma after 'FDA' in phrase about regulatory requirements - older had 'FDA, or any comparable' now reads 'FDA or any comparable'
- Notes:
- The older filing text appears truncated at the end ('given the dynamic nature of our business and the macroeconomic and geopolitical environment generally' is incomplete), limiting full comparison of closing sections
- Both filings appear truncated at their conclusion, preventing complete assessment of all Risk Factors section content
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 12 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 12 sells ($5M) — 1 selling insider
- Last 180 days0 buys · 19 sells ($8M) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-07. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about VERA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding VERA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 12,127,423
- Reported value $487,886,243
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
VERA had 15,281,960 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
VERA had 21.2% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.42 days to cover at the same settlement.
- Reported short interest (shares) 15,281,960
- Short interest (% of shares outstanding) 21.2%
- Prior settlement (shares) 15,081,995
- Reported change 1.33%
- Days to cover (reported) 9.42
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Calliditas Therapeutics (CALT)
- Travere Therapeutics (TVTX)
- Chinook Therapeutics (acquired by Novartis)
- Omeros (OMER)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare VERA vs…
VERA THERAPEUTICS INC CLASS A is found in…
Frequently asked questions
What does VERA THERAPEUTICS INC CLASS A (VERA) do?
Vera Therapeutics is a commercial-stage biotechnology company focused on developing and commercializing therapies for autoimmune diseases, with an initial emphasis on kidney disorders. Its lead commercial product is TRUTAKNA (atacicept-vymj), a B-cell activating factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) inhibitor used to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN).
What sector is VERA THERAPEUTICS INC CLASS A (VERA) in?
VERA THERAPEUTICS INC CLASS A (VERA) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are VERA THERAPEUTICS INC CLASS A's (VERA) competitors?
Notable peers of VERA THERAPEUTICS INC CLASS A (VERA) include Calliditas Therapeutics, Travere Therapeutics, Chinook Therapeutics (acquired by Novartis) and Omeros. This peer set is informational only — not financial advice.
Is VERA THERAPEUTICS INC CLASS A (VERA) overbought or oversold right now?
VERA THERAPEUTICS INC CLASS A (VERA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 46, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on VERA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.